Introduction Metabolically associated steatotic liver disease (MASLD) has become one of the most common causes of chronic liver disease worldwide, closely linked to the global epidemics of obesity and type 2 diabetes. The progressive form, metabolic dysfunction–associated steatohepatitis (MASH), can lead to fibrosis, cirrhosis, hepatocellular carcinoma, and liver transplantation.
Introduction
Metabolically associated steatotic liver disease (MASLD) has become one of the most common causes of chronic liver disease worldwide, closely linked to the global epidemics of obesity and type 2 diabetes. The progressive form, metabolic dysfunction–associated steatohepatitis (MASH), can lead to fibrosis, cirrhosis, hepatocellular carcinoma, and liver transplantation. Until recently, treatment options were limited mainly to lifestyle modification. Resmetirom, a selective thyroid hormone receptor-β (THR-β) agonist, represents a new pharmacologic therapy targeting hepatic steatosis and inflammation and is now approved for MASH with F2–F3 fibrosis. Beyond histologic improvements, its effect on health-related quality of life (HRQL) across the MASLD spectrum remained uncertain.
Summary
This analysis from the MAESTRO-NAFLD-1 trial and its open-label extension evaluated HRQL outcomes in patients with early MASH and MASH cirrhosis treated with resmetirom. A total of 1143 patients with early MASH and 180 with MASH cirrhosis were included. HRQL was assessed using disease-specific instruments, including CLDQ-NAFLD and LDQoL.
Patients with MASH cirrhosis had significantly poorer baseline quality-of-life scores compared with those with earlier disease. Treatment with resmetirom (80–100 mg) resulted in meaningful improvements in several HRQL domains, particularly worry, abdominal symptoms, and health distress, beginning by week 24 and sustained through week 52 and into year 2. Improvements were more pronounced in patients who achieved MRI-PDFF response, indicating a reduction in hepatic fat.
Overall, the study demonstrates that resmetirom not only improves liver pathology but also enhances disease-specific quality of life in patients across the MASLD spectrum, including those with cirrhosis, supporting its broader clinical benefit beyond histologic endpoints.
Introduction: Chronic hepatitis B (CHB), hepatic steatosis, and type 2 diabetes mellitus (T2DM) frequently coexist, creating a growing clinical challenge. This multinational study evaluated whether T2DM independently influences liver histology in treatment-naïve CHB patients with...
Introduction: Metabolic dysfunction-associated steatohepatitis (MASH) remains a leading cause of cirrhosis, liver failure, and hepatocellular carcinoma, with limited treatment options. This study evaluated DT-109, a novel glycine-based tripeptide, as a gut-targeted therapy aimed at restoring...
Introduction: Metabolic dysfunction-associated steatohepatitis (MASH) remains a leading cause of cirrhosis, liver failure, and hepatocellular carcinoma, with limited treatment options. This study evaluated DT-109, a novel glycine-based tripeptide, as a gut-targeted therapy aimed at restoring...
Introduction: Metabolic dysfunction-associated steatotic liver disease (MASLD) is closely linked to obesity, diabetes, and cardiovascular disease. While both tirzepatide and SGLT2 inhibitors improve metabolic health, comparative real-world data on long-term liver and cardiovascular outcomes have...
Introduction: GLP-1 receptor agonists (GLP-1RAs) have revolutionized obesity treatment, producing substantial weight loss and cardiometabolic benefits. However, many patients discontinue therapy because of cost, adverse effects, or limited access, and weight regain frequently follows. This...
Introduction: The treatment landscape for metabolic dysfunction-associated steatohepatitis (MASH) is evolving rapidly with the emergence of incretin-based therapies. Beyond improving weight and glycemic control, these agents are showing promise in resolving steatohepatitis and slowing fibrosis...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.